Industry News
Pharmaceutical Industry News
After a series of setbacks for…
After a series of setbacks for Sanofi’s tolebrutinib, the French company has scored a victory for the multiple sclerosis candidate.
Learn how Marken’s Laboratory…
Learn how Marken’s Laboratory Advantage improves speed, visibility and compliance to keep clinical trials on track.
An established sales force and…
An established sales force and payer authorization criteria will fuel a fast launch for Travere Therapeutics’ Filspari in its new indication and power the franchise to peak sales of $3.1 billion, Guggenheim Securities analysts predicted
Daiichi Sankyo has postponed its…
Daiichi Sankyo has postponed its annual report by two weeks, citing additional time needed to review “the supply plans for its oncology products portfolio and development pipeline.”
Roche’s Genentech unit is…
Roche’s Genentech unit is launching a new multimedia campaign aimed at sharing the stories of people living with diabetes and the impact the disease can have on their vision.
During Pfizer’s right-sizing push…
During Pfizer's right-sizing push after the COVID-19 pandemic, the company's multibillion-dollar cost-cutting campaign has affected its Ireland operations in several ways. Now, more employees in the country are set to lose their jobs by the
Merck & Co. unveiled the…
Merck & Co. unveiled the much-anticipated first look at its PD-1xVEGF bispecific data. China's Zai Lab is looking to go global. With a pipeline licensed from Hengrui Pharma, Kailera Therapeutics pulled off a record IPO.
Patients’ confidence in their…
Patients’ confidence in their ability to find answers about health questions and make informed decisions has plummeted in the past year, according to an Edelman survey.
Pfizer is kicking off the next…
Pfizer is kicking off the next stage of its cancer awareness program by teaming up with quarterback Fernando Mendoza.
Trump’s deal with the UK links…
Trump’s deal with the UK links tariffs to drug pricing. On this week’s "The Top Line," we examine whether similar agreements could follow.
Travis Smith was a very serious…
Travis Smith was a very serious baby. Born completely unable to hear, his mother Sierra struggled to see his personality shine through his mute world.
From cytotoxic safety to cold…
From cytotoxic safety to cold chain control, ADC manufacturing faces new pressures. Explore 7 real‑world handling considerations.
With Regeneron announcing a…
With Regeneron announcing a drug-pricing deal with the White House Thursday, all 17 companies targeted in a round of letters by the Trump administration last year have agreed to play ball with the President’s “most
While the scale of the currency…
While the scale of the currency headwinds in Roche’s first-quarter financial update caught many off guard, the company’s earnings call still featured much discussion on a pivotal pipeline prospect: the oral SERD drug giredestrant. The
In a brutal first quarter for…
In a brutal first quarter for Roche, key drugs in the company’s pharmaceutical division fall short of Wall Street expectations—big time. But the surging Swiss franc is only one piece of some disappointing sales figures.
The citizen petition takes issue…
The citizen petition takes issue with the FDA's new practice of publicly releasing batches of complete response letters in response to unapproved drug applications.
In its first-quarter presentation,…
In its first-quarter presentation, Sanofi highlighted that it has a “vigorous defense planned” to extend Dupixent’s exclusivity beyond March of 2031, when the U.S. patent protecting its compound expires. The blockbuster accounted for 40% of
With the recent launch of Novo…
With the recent launch of Novo Nordisk’s Wegovy pill opening the oral GLP-1 market for obesity, the company has now unveiled positive results that could tee up an expansion in semaglutide’s inaugural diabetes indication.
Nearly two-thirds of Americans are…
Nearly two-thirds of Americans are using artificial intelligence-based tools to seek medical information, while about one-third do not trust them.
Evonik plans to spend €80…
Evonik plans to spend €80 million ($93.5 million) to upgrade its bio fermentation production technology in Slovenská Ľupča, Slovakia, as part of an expansion that will add 50 new jobs.